Upload
kisaco-research
View
20
Download
1
Embed Size (px)
Citation preview
ARETEON PTE LTD亚绿基公司
We create possibilities in veterinary therapeutics
INVESTMENT/BUSINESS OPPORTUNITY
PATENTED, NON-BACTERIAL
RESISTANCEANTIMICROBIAL AND ANTI-FUNGAL DRUG
© Areteon Pte Ltd
2ANTIMICROBIAL DRUG RESISTANCE
1. The first anti-microbial drug was discovered in 1929 : Penicillin
2. The last true antibiotic was discovered in 1960s
3. Today, there are only 7 antibiotic scaffolds. All the so-called recent “discoveries” are based on manipulating the existing scaffolds. This encourages multi-drug resistance very rapidly
© Areteon Pte Ltd
3ANTIMICROBIAL DRUG RESISTANCE
Antimicrobial drugs need to enter the bacterium to
be able to kill the bacterium or stop it from
replicating
Mode of action #1
© Areteon Pte Ltd
4ANTIMICROBIAL DRUG RESISTANCE
Mode of action #2
Antimicrobial drugs need to breakthrough the
biofilm that protects the bacteria
© Areteon Pte Ltd
5DMDC: NOVEL MODE OF ACTIONPatent pending; PCT/SG2014/000053
Poly-cationic chitosan-based polymer
Quaternary ammonium (positively charged)Glucosamine moiety
PEG
© Areteon Pte Ltd
6DMDC: NOVEL MODE OF ACTIONPatent pending; PCT/SG2014/000053
RNA
DNA
Cell wall(negatively charged)
Staphylococcus aureus
DMDC(positively charged)
Electrostatic bonding
© Areteon Pte Ltd
7DMDC: NOVEL MODE OF ACTIONPatent pending; PCT/SG2014/000053
Staphylococcus aureus
DMDC(positively charged)
Bacterial lysis = bactericidal
© Areteon Pte Ltd
8DMDC: NOVEL MODE OF ACTIONPatent pending; PCT/SG2014/000053
Does not need to penetrate the bacterium
Cannot be neutralized by the enzymes in the
bacterium
No risk of bacterial resistance to DMDC
© Areteon Pte Ltd
9DMDC: NOVEL MODE OF ACTIONPatent pending; PCT/SG2014/000053
Treatment by
DMDC
Electron-microscopy of destruction of S. aureus
Perforation of cell wall = Death of bacteria
© Areteon Pte Ltd
10DMDC: TRIALS CONDUCTEDPatent pending; PCT/SG2014/000053
Efficacy: 4% shampoo formulation
Observation parameters
Treatment periodDay 0 Day 7 Day 14 Day 21
Pruritus1
OwnerClinician
4.334.00
3.333.33
3.002.67
2.332.33
Bacterial Load2
PapulesPustulesSkin flakes
2.282.562.00
1.672.111.50
1.441.721.00
0.560.940.00
Symptoms 3
PapulesPustulesSkin flakesScabs/Dandruff
3.673.002.503.50
3.672.672.502.50
3.002.331.502.50
2.332.331.502.00
Fur Coat4
ShineOdourFur loss
4.003.674.00
3.672.674.00
3.002.334.00
2.331.673.00
© Areteon Pte Ltd
11DMDC: 3X Minimum Inhibitory Concentration Trials Conducted for “OralGarde” Veterinary Mouth-Spray Patent pending; PCT/SG2014/000053
S. aureus (μg/mL) E. coli (μg/mL) P. aeruginosa (μg/mL) MRSA (μg/mL)
12.5 25 25 15
12.5 25 25 15
12.5 25 25 15
© Areteon Pte Ltd
12DMDC: TRIALS CONDUCTEDPatent pending; PCT/SG2014/000053
Safety: Acute oral toxicity (OECD guideline 423)
1. LD50 > 2,000 mg/kg of body weight.
2. All rats appeared normal thereafter till euthanized. No untoward clinical signs were observed during this period.
3. All rats did not have significant lesions observed on gross pathology.
© Areteon Pte Ltd
13DMDC: MILESTONES ACHIEVEDPatent pending; PCT/SG2014/000053
S$600,000 seed funding by business
angel in May 2012
Successful completion of preliminary
trials on potency,
efficacy and safety on Sep
2013
Optimization of chemical synthesis at
mass - production scale with
significantly improved potency.
Sales launch in Q1 2017 new Topical
Products formulated with DMDC
significantly improved potency and raise
capital for expansion.
S$725,000 Singapore
government funding between Jan 2013 and Dec
2015
© Areteon Pte Ltd
14
ARETEON PTE LTD亚绿基公司
We create possibilities in veterinary therapeutics
ARETEON PTE LTD19 Tai Seng Avenue,
#06-19 Home-Fix Building,
Singapore 534054
THANK YOU !